These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 9119165)

  • 21. Avoiding viral contamination in biotechnological and pharmaceutical processes.
    Henzler HJ; Kaiser K
    Nat Biotechnol; 1998 Nov; 16(11):1077-9. PubMed ID: 9831040
    [No Abstract]   [Full Text] [Related]  

  • 22. Considerations in performing virus spiking experiments and process validation studies.
    Darling AJ
    Dev Biol Stand; 1993; 81():221-9. PubMed ID: 8174806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proceedings of the 2017 Viral Clearance Symposium Session 5: Facility Risk Mitigation.
    Ma J; Kreil TR
    PDA J Pharm Sci Technol; 2018; 72(5):511-515. PubMed ID: 30030359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk reduction in biotherapeutic products.
    Ill CR; Dehghani H
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):296-304. PubMed ID: 19333875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Theoretical considerations on viral inactivation or elimination.
    Willkommen H; Löwer J
    Dev Biol Stand; 1993; 81():109-16. PubMed ID: 8174793
    [No Abstract]   [Full Text] [Related]  

  • 26. European Regulatory guidance on virus safety of recombinant proteins, monoclonal antibodies and plasma derived medicinal products.
    Celis P; Silvester G
    Dev Biol (Basel); 2004; 118():3-10. PubMed ID: 15645667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety assurance for biologics manufactured in mammalian cell cultures: a multitiered strategy.
    Chen D
    Adv Biochem Eng Biotechnol; 2014; 139():167-83. PubMed ID: 23719711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strategies for the validation of viral inactivation in biologic products.
    Aronson DL
    Prog Clin Biol Res; 1990; 324():137-49. PubMed ID: 2408050
    [No Abstract]   [Full Text] [Related]  

  • 29. Real time quantitative PCR as a method to evaluate simian virus 40 removal during pharmaceutical protein purification.
    Shi L; Norling LA; Lau AS; Krejci S; Laney AJ; Xu Y
    Biologicals; 1999 Sep; 27(3):253-62. PubMed ID: 10652180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Scope and practicality of in vivo testing for adventitious agents.
    Whiteman MD
    Dev Biol (Basel); 2006; 123():147-52; discussion 183-97. PubMed ID: 16566442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Virus removal from factor IX by filtration: validation of the integrity test and effect of manufacturing process conditions.
    Roberts PL; Feldman P; Crombie D; Walker C; Lowery K
    Biologicals; 2010 Mar; 38(2):303-10. PubMed ID: 20089418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The removal of viruses during the purification of equine antisera using filtration aids Hyflo Super-Cel and Fulmon Super A.
    Cameron-Smith R; Miloradovic L; Cheyne I; Healy K
    Biologicals; 2000 Sep; 28(3):169-74. PubMed ID: 10964443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Viral validation design of a manufacturing process.
    Larzul D
    Dev Biol Stand; 1999; 99():139-50. PubMed ID: 10404885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Viral safety and clearance evaluation--implications for process change and comparability.
    Dinowitz M
    Dev Biol (Basel); 2002; 109():121-6. PubMed ID: 12434921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Viral safety of biological medicinal products].
    Stühler A; Blümel J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1198-202. PubMed ID: 25123140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virus elimination and validation.
    Boschetti N; Johnston A
    Methods Mol Biol; 2005; 308():209-19. PubMed ID: 16082037
    [No Abstract]   [Full Text] [Related]  

  • 37. Protein purification: aspects of processes for pharmaceutical products.
    Berthold W; Walter J
    Biologicals; 1994 Jun; 22(2):135-50. PubMed ID: 7917230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anion exchange chromatography provides a robust, predictable process to ensure viral safety of biotechnology products.
    Strauss DM; Gorrell J; Plancarte M; Blank GS; Chen Q; Yang B
    Biotechnol Bioeng; 2009 Jan; 102(1):168-75. PubMed ID: 18683259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Viral inactivation of intramuscular immune serum globulins.
    Alonso WR; Trukawinski S; Savage M; Tenold RA; Hammond DJ
    Biologicals; 2000 Mar; 28(1):5-15. PubMed ID: 10799050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inactivation of retroviruses in biologicals manufactured for human use.
    Hilfenhaus J; Gregersen JP; Müller H; Nowak T; Pranter W
    Dev Biol Stand; 1991; 75():159-69. PubMed ID: 1794617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.